Intermediate Grade Lung Neuroendocrine Neoplasm clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This randomized phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
at UC Davis UCSF
Our lead scientists for Intermediate Grade Lung Neuroendocrine Neoplasm research studies include Emily K. Bergsland.